Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan;94(1):103-109.
doi: 10.1016/j.mayocp.2018.08.028.

Reconciling Opportunistic and Population Screening in Clinical Genomics

Affiliations
Review

Reconciling Opportunistic and Population Screening in Clinical Genomics

Kyle B Brothers et al. Mayo Clin Proc. 2019 Jan.

Abstract

Opportunistic genomic screening is becoming increasingly common as laboratories adopt recommendations to report secondary genomic findings. In parallel, interest in using genome sequencing as a population screening test has grown rapidly. We consider here 3 potential applications of genome sequencing for preventive medicine: (1) provider-ordered predispositional testing in healthy adults, (2) indication-based testing with opportunistic screening of secondary results, and (3) population screening in the public health context. We conclude that despite superficial similarities, there are important and fundamental differences in the way medical risks and benefits can be addressed in these 3 contexts. Recommendations to report secondary genomic findings should not be interpreted as an endorsement of population genomic screening. Ongoing work is developing the evidence that will be needed to fully justify current and future initiatives in population genomic screening. Ongoing work is developing the evidence that will be needed to fully justify current and future initiatives in population genomic screening.

PubMed Disclaimer

Conflict of interest statement

Competing Interests

Dr. Green receives compensation for speaking or consultation from AIA, Helix, Ohana, Prudential and Veritas; and is co-founder, advisor and equity holder in Genome Medical, Inc.

Comment in

References

    1. Biesecker LG, Green RC. Diagnostic clinical genome and exome sequencing. N Engl J Med. 2014;370(25):2418–2425. - PubMed
    1. Offit K Decade in review--genomics: a decade of discovery in cancer genomics. Nat Rev Clin Oncol. 2014;11(11):632–634. - PubMed
    1. Weng L, Zhang L, Peng Y, Huang RS. Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy. Pharmacogenomics. 2013;14(3):315–324. - PMC - PubMed
    1. Green RC, Berg JS, Grody WW, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med. 2013;15(7):565–574. - PMC - PubMed
    1. ACMG Board of Directors. ACMG policy statement: updated recommendations regarding analysis and reporting of secondary findings in clinical genome-scale sequencing. Genet Med. 2015;17(1):68–69. - PubMed

Publication types

LinkOut - more resources